As a previously mentioned PKC inhibitor, midostaurin has not demonstrated efficacy in early-phase studies as monotherapy in low-grade lymphoproliferative disorders and metastatic melanoma and as combination therapy in various solid tumors [64,65,66]. This evidence concerns the gene PRRT2 and lymphoproliferative syndrome.